Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
This is one of the most important articles of the year. It discusses the results of the first small ICT-107 vaccine trial. The key outcome: "At a median follow-up of 40.1 months, six of 16 newly diagnosed GBM patients showed no evidence of tumor recurrence. "
Notice the Acknowledgments section: This study was supported by funding from Musella Foundation For Brain Tumor Research & Information, Inc. and ImmunoCellular Therapeutics Ltd.
This confirms that we (The Musella Foundation) seek out and fund the best research. Not only did we fund this project, but we also funded the early development on one of the targets of the vaccine. This is a perfect example of how important YOUR donations are. People always ask me if making donations can make a difference. This proves it.
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://www.springerlink.com/content/n0018574g9m4v587/fulltext.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines